Home » Archives by category » Pharma Industry News
Merck to acquire coronavirus vaccine candidate developer Themis Bioscience

Merck to acquire coronavirus vaccine candidate developer Themis Bioscience

Merck acquisition of Themis Bioscience : Merck has signed a deal to acquire Themis Bioscience, an Austrian vaccine developer for an undisclosed price with an objective to gain access to the latter’s coronavirus vaccine candidate. Themis Bioscience by leveraging its measles virus vector platform has developed a pipeline of vaccine candidates and immune-modulatory therapies. Recently, […]

Comet Bio reports positive results for prebiotic Arrabina

Comet Bio said that Arrabina, its arabinoxylan plant fiber extract, has delivered positive clinical trial results with its gastrointestinal (GI) tolerability no different than placebo. The results are from a completed randomized, placebo-controlled, crossover clinical trial that assessed the gastrointestinal tolerability and prebiotic effects of Arrabina. Comet Bio said that results show that consumers can take […]

Continue reading …
Sorrento Therapeutics says STI-1499 fully inhibited SARS-CoV-2 virus

Sorrento Therapeutics said that STI-1499, its anti-SARS-CoV-2 antibody, showed 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration. The US biotech company will look to create an antibody cocktail product that will work as a protective shield against SARS-CoV-2 coronavirus infection and stay effective even […]

Continue reading …
HKBU-led researchers develop EBV drug for nasopharyngeal cancer

A research team headed by Hong Kong Baptist University (HKBU) claims to have developed a novel anti-Epstein-Barr virus (EBV) drug for the treatment of nasopharyngeal cancer and other EBV-related cancers. The novel anti-viral targeted drug can disrupt a viral protein produced by EBV selectively, thereby resulting in shrinkage of tumors caused by the human herpesvirus […]

Continue reading …
AbbVie wraps up $63bn acquisition of Irish drugmaker Allergan

US biopharma company AbbVie has wrapped up its previously announced $63 billion acquisition of Irish drugmaker Allergan following receipt of all the required approvals from all government authorities and approval from the Irish High Court. AbbVie acquisition of Allergan, which was announced in June 2019, is said to expand and diversify significantly the former’s revenue […]

Continue reading …
AbbVie acquisition of Allergan gets antitrust clearance from US FTC

AbbVie acquisition of Allergan update : US biopharma company AbbVie has secured clearance from the US Federal Trade Commission (FTC) for its previously announced $63 billion acquisition of Botox developer Allergan. According to AbbVie, the approval from the FTC satisfies all the necessary antitrust clearances required for the closing of the cash cum stock deal […]

Continue reading …
Alexion Pharmaceuticals to acquire Portola Pharmaceuticals for $1.4bn

Alexion acquisition of Portola : Alexion Pharmaceuticals has agreed to acquire Portola Pharmaceuticals, a commercial-stage biopharma company focused on life-threatening blood-related disorders, for $1.41 billion. Portola Pharmaceuticals developed Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], which is marketed as Ondexxya in Europe. The drug is the first and only approved Factor Xa inhibitor reversal agent, and […]

Continue reading …
Italy’s Menarini to acquire US biopharma company Stemline Therapeutics

Menarini acquisition of Stemline : Menarini Group, an Italian pharma and diagnostics company, has agreed to acquire US biopharma company Stemline Therapeutics in a deal worth up to $677 million. Stemline Therapeutics is engaged in the development and commercialization of novel oncology therapeutics. Its acquisition enables Menarini Group to establish its footprint in the US […]

Continue reading …
BioMarin, DiNAQOR to develop gene therapies for rare genetic cardiomyopathies

BioMarin Pharmaceutical has signed a preclinical collaboration and license deal with Swiss gene therapy platform company DiNAQOR to develop novel gene therapies for the treatment of rare genetic cardiomyopathies. DiNAQOR will get an undisclosed upfront payment and will stand to receive development, regulatory and commercial milestones on product sales apart from tiered royalties on global […]

Continue reading …
Trio Pharmaceuticals, Aji Bio-Pharma to co-develop antibody drug conjugates

Trio Pharmaceuticals and Ajinomoto Bio-Pharma Services (Aji Bio-Pharma) have entered into a development collaboration agreement to assess AJICAP, a site-specific conjugation technology offered by the latter for the development of dual action antibody drug conjugates TRIObody Drug Conjugates (TDCs). Aji Bio-Pharma is a provider of biopharmaceutical contract development and manufacturing services, while Trio Pharmaceuticals is […]

Continue reading …
Page 1 of 26123Next ›Last »